Thursday, February 8, 2007

Live Podcast Interview: Jim Edwards

The Pharma Blogosphere reader survey is going very nicely and I will soon have some results to share.

But if you are like me, you may want to know more about the people behind the blogs. Where did they come from? Why are they doing this? What are their qualifications? What's their favorite book? What blogs do THEY read on a regular basis? etc.

I've been lining up several Pharma Blogosphere bloggers as guests on my Pharma Marketing Talk live podcast series. The first such guest is Jim Edwards, Senior Editor, Brandweek and motivating force behind BrandweekNRX. The topic of this podcast is "Journalist Bloggers: An Interview with Jim Edwards." Read more about it here.

That's Jim over there on the left. I bet a lot people tell him he looks like Jeff Bezos. I was going to do a morph between Jim and Jeff but decided life's too short for that.

The topic I'd like to pursue with Jim is "Will blogging corrupt journalists or vice versa?" The gauntlet on this issue was laid down by Matt Holt over at The Health Care Blog (see "Journalistic Suicide or Blog Assimilation?").

I may just invite Matt to join in.

  • Air Date & Time: Tuesday, February 20, 2007, 1 PM Eastern US
  • Duration: Approx. 30-45 minutes
Go to the Pharma Marketing Talk Channel Page at the designated time to listen live via the Internet; or go there afterward to listen to audio archive.

You can call in by phone to ask questions or participate in the discussion (go here for instructions on how to do that. Please don't call in if you just want to listen.

Other guests scheduled for future podcasts include:
  • Fard Johnmar (HealthcareVox): Wednesday, February 28, 2007, 1 PM Eastern
  • Mark Senak (EyeOnFDA): Tuesday, March 6, 2007, 1 PM Eastern
  • Cary Byrd (eDrugSearch Blog): Tuesday, March 20, 2007, 1 PM Eastern
Others to be announced.

BTW, drop Insider at PharmaGossip a note and urge him to at least call in to one of these. He can talk through a gizmo to disguise his voice if he thinks that's necessary.

No comments: